Upload
vlerickalumni
View
45
Download
2
Tags:
Embed Size (px)
Citation preview
SOME PHARMA FINANCIALS
PROF. DR. WOUTER DE MAESENEIRE
DISCLAIMER
I am not a pharma/healthcare expert
But I did quite some work for student in-company projects or customized trainings for
Pfizer, J&J (Janssen), Arseus, Capsugel, UCB, Boehringher-Inghelheim,…
IRC MFM last year: UCB
I wrote a case on BigPharma vs Small BiotechFSA
I’ll give a broad overview of some of the issues
© Vlerick Business School3
© Vlerick Business School
PROFIT AND LOSS ACCOUNT/INCOME STATEMENT
4
© Vlerick Business School
APPLE: PROFIT AND LOSS ACCOUNT (P&L)
5
© Vlerick Business School
DO YOU KNOW…
6
© Vlerick Business School
AN UNFORESEEN OUTCOME…
7
© Vlerick Business School
LIPITOR
Peak sales
Cumulative sales (1996-2012)
8
© Vlerick Business School
PFIZER: PROFIT AND LOSS ACCOUNT (P&L)
9
12
13
14
15
16
17
18
© Vlerick Business School
GALAPAGOS
19
© Vlerick Business School
GALAPAGOS: P&L
20
© Vlerick Business School21
© Vlerick Business School
GALAPAGOS: ASSETS
22
© Vlerick Business School
GALAPAGOS: EQUITY AND LIABILITIES
23
© Vlerick Business School
GALAPAGOS: CASH FLOW STATEMENT
24
© Vlerick Business School
A LOT OF BIG PHARMA & SMALL BIOTECHDEALS
M&A, alliances, milestone payments, co-development, licencsing out,…
Clear complementarities
25